ABT vs LFMDP · P/E 25, rev $44.33B vs rev $194.1M
Abbott Laboratories (ABT) versus LifeMD Inc Preferred Series A (LFMDP) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
LifeMD Inc Preferred Series A (LFMDP) is a health information services company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported LFMDP revenue for 2025-12-31 was $194.1M. Net income was $14.4M. Revenue was down 8.7% from 2024-12-31 to 2025-12-31. LFMDP currently screens at market cap $0.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. LFMDP currently screens at market cap $0.
Not investment advice. Open the ABT and LFMDP stock pages for the full models.
Not investment advice.